PharmaFocus Today – Page 320 – media

Ketone supplements used by some athletes may worsen performance

Kinesiologists at McMaster University have found ketone supplements, used by some athletes hoping to cross the finish line faster, may in fact worsen performance. The new study, published in the latest print edition of the International Journal of Sport Nutrition and Exercise Metabolism, tackles contradictory research findings related to the effectiveness of ketone supplements, which have gained popularity among athletes seeking a competitive advantage. Some previously published studies had shown the supplements improve performance, while others have reported they had no effect or even worsened performance. Natural ketones can serve as fuels for the brain and muscles. A ketogenic diet –characterized by very low carbohydrate and typically high fat intake – causes the body to produce more organic ketone compounds and increase their use for energy. Ketone supplements speed up that process, without the strict diet. One of the main perceived benefits is that ketones may serve as an alternative ...
- Source: drugdu
- 116
- June 23, 2023
Study finds that the human brain reactivates mental representations of past events during new experiences

Neuroscience studies have showed that as mice and other rodents navigate a maze, their brain often “replays” relevant past events. This mental replaying of events, such as the route taken until reaching their current position, could help rodents create a mental map of the spatial environment, and understand their position in it. Researchers at University College London and Queen Mary University of London recently explored the possibility that the human brain also replays past events to make sense of evolving, non-spatial experiences. Their findings, published in Nature Neuroscience, confirms this hypothesis and suggests that the process through which the human brain reactivates these events might be far more complex than that observed in rodents. “We know that the brain can ‘replay’ information that was encountered in the past, although this has mainly been studied in navigation tasks involving rodents,” Avital Hahamy, one of the researchers who carried out the study, ...
- Source: drugdu
- 210
- June 20, 2023
Research reveals a potential gap in recommended care for people with obesity and overweight

By being undiagnosed or untreated, a significant fraction of people with obesity or overweight are not getting the recommended care, despite an increase in new treatment options, according to research being presented on June 17 at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill. “The number of people with obesity is high and rising in the adult U.S. population. Obesity is a complex and expensive disease that has been implicated in many chronic conditions including high blood pressure, diabetes, and cardiovascular diseases,” said Kyrian Ezendu, Ph.D., an Eli Lilly and Company advisor on benefit-risk research. “Medications to treat obesity are an integral part of long-term care for people with excess weight and are recommended for people with obesity or people with overweight and at least one obesity-related condition.” Ezendu and colleagues used data from linked electronic health records and insurance claims of people ages 18 to 80 years ...
- Source: drugdu
- 251
- June 20, 2023
Radioactive iodine or surgery linked to decreased mortality risk in patients with hyperthyroidism

Hyperthyroidism treatment like radioactive iodine or surgery was associated with a decreased risk for death, according to research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago. Kristien Boelaert (M.D., Ph.D., Professor of Endocrinology, University of Birmingham, United Kingdom) said, “Hyperthyroidism or an overactive thyroid gland is common, affecting up to 3% of the population, and is associated with long-term adverse cardiac and metabolic consequences. The optimal treatment choice remains unclear.” Boelaert and colleagues identified 55,318 patients with newly diagnosed hyperthyroidism, treated with antithyroid drugs (ATD; 77.6%), radioiodine (14.6%), or thyroidectomy (7.8%) from a U.K. population-based electronic health record database for the EGRET Study. They examined all-cause mortality, major cardiovascular events (MACE: cardiovascular death, heart failure, or stroke), and post-treatment obesity. The average follow-up was roughly 12 years. Those treated with antithyroid drugs had an estimated mean survival of 12 years, according to the data. Survival ...
- Source: drugdu
- 110
- June 20, 2023
Tessa Therapeutics Hodgkin’s Lymphoma CAR-T therapy shows promising Phase I data

Clinical-stage cell therapy company Tessa Therapeutics have announced positive safety and efficacy data from the trial (NCT04288726 of TT11X, its off-the-shelf CD30.CAR-modified EBVST (Epstein Barr Virus Specific T Cells) therapy in patients with relapsed or refractory (R/R) Hodgkin lymphoma. In tandem with Baylor College of Medicine, Tessa enrolled 18 patients with R/R Hodgkin’s Lymphoma in the trial, all of whom had been heavily pre-treated. Patients were administered with TT11X across four dosing levels, resulting in an overall response rate (ORR) of 78%. Higher doses produced improved clinical response, and no dose-limiting toxicities were observed. Treatment works by utilising highly specialised T-cells able to recognize and kill infected cells, whilst activating the body’s immune system to produce a coordinated response. The company claimed that early trials have demonstrated a strong safety profile and efficacy. TT11X is the lead allogenic cell therapy in Tessa’s planned pipeline of treatments built with its CD30.CAR ...
- Source: drugdu
- 169
- June 20, 2023
ANeuroTech shares plans for major depressive disorder pivotal programme

Belgium-headquartered ANeuroTech is participating in a Series B round, which will raise up to $150m to power the pivotal programme of its lead candidate ANT01 for use as an adjunctive treatment for major depressive disorder (MDD). This includes the company’s upcoming Phase IIIb trial, but also another Phase III study and a long-term safety trial, said ANeuroTech CEO Eric Buntinx in an interview with Pharmaceutical Technology. The company has already contacted funds based in Europe and in the US, said Buntinx. He added that ANeuroTech is speaking to more than ten different parties. The company plans to finish the round by September or October at the latest. ANeuroTech previously raised an undisclosed amount of capital as part of a Series A round, which featured investment from impact finance firm KOIS. ANT01 consists of a 15mg dose of pipamperone, which is a serotonin-2A and dopamine-4 blocker, per the company’s website. While ...
- Source: drugdu
- 117
- June 20, 2023
Race for universal flu vaccine ramps up as Osivax kicks off Phase IIa trial

France-based biotech company Osivax has thrown its hat into the influenza ring by dosing the first subject with its vaccine candidate OVX836. The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs). The developer has tested OVX836 in four completed clinical trials. In a company statement announcing the latest trial kick-off, Osivax said a recently completed separate Phase IIa trial demonstrated that the candidate in combination with QIVs had a good safety profile with no impairment of immune response by the QIVs. The aim of the latest ongoing trial is to evaluate the vaccine in a larger and more diverse population. The company aims to enrol more than 500 participants aged 18-60 across multiple clinical sites in Australia. The OVX836 vaccine targets nucleoprotein – a conserved internal antigen. Internal antigens, unlike surface antigens, have a lower probability of ...
- Source: drugdu
- 101
- June 20, 2023
MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker

Merck (MSD) has announced updated results with Keytruda (pembrolizumab) in the Phase III Keynote-811 trial, which opens up the possibility of changing the checkpoint inhibitor’s label in HER2-positive gastric or GEJ adenocarcinoma so it’s based on the tumour’s PD-L1 biomarker status. The Phase III Keynote-811 study (NCT03615326) met its progression-free survival (PFS) endpoint for treating human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in the intent-to-treat population. A pre-specified interim analysis of trial data found a “statistically significant” improvement in PFS compared to placebo in the ITT group. In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum. Based on the latest Keynote-811 results, MSD now plans to work with the ...
- Source: drugdu
- 153
- June 20, 2023
Single hospital study finds transgender teenagers rarely choose to discontinue hormone therapy

A three-year-long retrospective cohort study of a single Atlanta hospital’s patient population found transgender and gender-diverse teenagers rarely chose to discontinue gender-affirming hormone therapy, according to a study being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill. Among 82 transgender and gender-diverse adolescents treated at an academic pediatric endocrinology center from beginning of 2016 to end of 2018, only three chose to halt gender-affirming hormone therapy. None of them resumed identifying as their assigned sex at birth. One participant stopped hormonal therapy due to insurance issues, one participant stopped treatment temporarily to conceive a baby, and one stopped testosterone to transition to a nonbinary gender. “In the infrequent cases in which a person discontinues their gender-affirming hormone therapy, it is often due to external factors as opposed to true retransitioning to the sex assigned at birth,” said lead researcher Pranav Gupta, M.D., a fellow at ...
- Source: drugdu
- 106
- June 20, 2023
Medivis Snags $20M to Enhance Surgical Navigation With Augmented Reality

Gone are the days when augmented reality’s primary use cases centered on gaming and entertainment. Investors are now betting on the technology’s promise to enhance surgical navigation. This shift is evidenced by Medivis’ recent funding round — the New York City-based medical augmented reality (AR) company raised $20 million in Series A financing on Tuesday. The round, which takes Medivis’ total funding to $25 million, was led by Thrive Capital. Other investors included Mayo Clinic, Initialized Capital, Disney CEO Bob Iger and NBA star Kevin Durant. Medivis was founded in 2016 by neurosurgeon Osamah Choudhry, who serves as CEO, and radiologist Christopher Morley, who serves as president. Their mission has always been to establish AR as the new standard in surgical navigation, Choudhry shared in a recent interview. “Traditionally, surgeons have relied on 2D flat images, requiring them to mentally reconstruct their patient images into a 3D representation. However, with ...
- Source: drugdu
- 117
- June 17, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.